Select one or more newsletters to continue. Evid Based Ment Health. doi: 10.2165/11310820-000000000-00000. Name must be less than 100 characters Br J Psychiatry. 2007 Jul;191:86; author reply 87. 2011 Sep;217(1):127-42. doi: 10.1007/s00213-011-2262-z. COVID-19 is an emerging, rapidly evolving situation. The following information is NOT intended to endorse any particular medication. Epub 2014 Sep 12.Innamorati M, Baratta S, Di Vittorio C, Lester D, Girardi P, Pompili M, Amore M.Schizophr Res Treatment.
Brexpiprazole (Rxulti®, Rexulti®) is an oral atypical antipsychotic agent approved for the treatment of schizophrenia in the EU (in adult patients) and the USA, as well as in some other countries, including Japan. . 2007 Feb;10(1):14. 2007 Feb;10(1):14. doi: 10.1136/ebmh.10.1.14.Br J Psychiatry. Name must be less than 100 characters [email protected] Comment in Evid Based Ment Health. . In summary, the data available so far indicate that the optimum dose for aripiprazole is 10 mg/day and that doses above 20 mg/day provide no additional benefit. 2002;16(11):779-86; discussion 787-8. doi: 10.2165/00023210-200216110-00008.Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, L'Italien G, McQuade RD, Beuzen JN.Eur Psychiatry. Aripiprazole is a new drug for the treatment of adults with schizophrenia. Name must be less than 100 characters Unable to load your collection due to an error Please enable it to take advantage of the complete set of features! Aripiprazole is a new drug for the treatment of adults with schizophrenia. Furthermore, following 26 weeks' treatment, the time to relapse was significantly longer for patients with chronic, stabilized schizophrenia receiving aripiprazole compared with those receiving placebo. 2013;2013:423205. doi: 10.1155/2013/423205. Springer 2007 Sep;164(9):1411-7. doi: 10.1176/appi.ajp.2007.06091479.Kegeles LS, Slifstein M, Frankle WG, Xu X, Hackett E, Bae SA, Gonzales R, Kim JH, Alvarez B, Gil R, Laruelle M, Abi-Dargham A.Neuropsychopharmacology. Schizophrenia Research: “Head-to-head comparisons of metabolic side effects of second-generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.” eCollection 2018 May 1. Unable to load your collection due to an error 2014 Jul;74(10):1097-110. doi: 10.1007/s40265-014-0231-7.Korean J Physiol Pharmacol. Author information: (1)Adis, Auckland, New Zealand. Croxtall JD(1). COVID-19 is an emerging, rapidly evolving situation. Unable to load your delegates due to an error 2019 Apr 1;76(4):409-417. doi: 10.1001/jamapsychiatry.2018.4149.Drugs. As a consequence, aripiprazole may provide a more cost-effective treatment option compared with other atypical antipsychotics. Cambridge University Press Epub 2008 Dec 2.Clin Ther. Available for Android and iOS devices. Aripiprazole: a review of its use in the management of schizophrenia in adults. In addition, the highest response rate is seen at 10 mg/day. Clipboard, Search History, and several other advanced features are temporarily unavailable.
In addition, the highest response rate is seen at 10 mg/day.
Epub 2014 Jul 1.Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, Stringfellow J, Ingenito G, Marder SR.Arch Gen Psychiatry. doi: 10.2165/11208400-000000000-00000. Conclusions: Based on the evidence reviewed, aripiprazole monotherapy appears to be effective and well tolerated in treating the positive, negative, and cognitive symptoms of schizophrenia and schizoaffective disorder. Brexpiprazole (Rxulti ®, Rexulti ®) is an oral atypical antipsychotic agent approved for the treatment of schizophrenia in the EU (in adult patients) and the USA, as well as in some other countries, including Japan.Like aripiprazole, it is a partial agonist at dopamine D 2 and serotonin 5-HT 1A receptors and an antagonist at serotonin 5-HT 2A receptors. Epub 2013 Jan 21.Segnitz N, Ferbert T, Schmitt A, Gass P, Gebicke-Haerter PJ, Zink M.Psychopharmacology (Berl). Author information: (1)Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.